Skip to main content
. 2026 May 9. Online ahead of print. doi: 10.1159/000552461

Table 2.

Univariate and multivariate logistic regression analysis

Variables Univariate analysis Multivariate analysis
OR (95% CI) p value OR (95% CI) p value
Male, n (%) 1.55 (0.90∼2.69) 0.116 ​ ​
Hypertension, n (%) 1.53 (0.86∼2.71) 0.151 ​ ​
Diabetes mellitus, n (%) 1.37 (0.76∼2.47) 0.295 ​ ​
Smoking, n (%) 0.85 (0.47∼1.55) 0.604 ​ ​
Killip >1, n (%) 1.72 (0.87∼3.40) 0.118 ​ ​
LAD, n (%) 2.71 (1.51∼4.87) <0.001 3.00 (1.61∼5.59) <0.001
LCX, n (%) 0.59 (0.23∼1.53) 0.279 ​ ​
RCA, n (%) 0.53 (0.28∼1.02) 0.056 ​ ​
ACEI/ARB, n (%) 1.01 (0.58∼1.75) 0.972 ​ ​
Beta-blockers, n (%) 0.62 (0.31∼1.25) 0.183 ​ ​
Age, years 1.01 (0.99∼1.04) 0.312 ​ ​
Heart rate, bpm 1.00 (0.98∼1.02) 0.907 ​ ​
SBP, mmHg 0.99 (0.98∼1.01) 0.348 ​ ​
DBP, mmHg 1.00 (0.98∼1.02) 0.830 ​ ​
LVEF, % 0.98 (0.96∼1.00) 0.045 0.98 (0.95∼1.00) 0.077
Left atrial diameter, mm 1.03 (1.00∼1.07) 0.162 ​ ​
CRP, mg/L 1.01 (1.00∼1.01) 0.015 1.01 (1.00∼1.01) 0.007
hs-TnT, pg/mL 1.75 (1.01∼3.05) 0.049 1.76 (0.96∼3.24) 0.067
sST2, ng/mL 1.01 (1.01∼1.02) <0.001 1.02 (1.01∼1.02) <0.001
BMI, kg/m2 0.95 (0.85∼1.06) 0.330 ​ ​
NT-proBNP, pg/mL 2.04 (1.21∼3.42) 0.007 2.21 (1.25∼3.91) 0.006
eGFR, mL/min/1.73 m2 1.00 (0.99∼1.02) 0.556 ​ ​
FBG, mmol/L 1.03 (0.94∼1.12) 0.529 ​ ​
TC, mmol/L 1.13 (0.86∼1.48) 0.375 ​ ​
TG, mmol/L 1.16 (0.96∼1.41) 0.126 ​ ​
HDL, mmol/L 0.64 (0.19∼2.16) 0.475 ​ ​
LDL, mmol/L 1.15 (0.85∼1.56) 0.366 ​ ​

NOAF, new-onset atrial fibrillation; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; hs-TnT, high-sensitivity troponin T; NT-proBNP, N-terminal pro-B-type natriuretic peptide; CRP, C-reactive protein; LDL, low-density leptin cholesterol; HDL, high-density leptin cholesterol; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; LVEF, left ventricular ejection fraction; LAD, left anterior descending; LCX, left circumflex artery; RCA, right coronary artery; LM, left main coronary artery; sST2, soluble suppression of tumorigenicity 2.